Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pacific Biosciences of California, Inc. before investing.

In this article, we go over a few key elements for understanding Pacific Biosciences of California, Inc.’s stock price such as:

• Pacific Biosciences of California, Inc.’s current stock price and volume
• Why Pacific Biosciences of California, Inc.’s stock price changed recently
• Upgrades and downgrades for PACB from analysts
• PACB’s stock price momentum as measured by its relative strength

About Pacific Biosciences of California, Inc. (PACB)

Before we jump into Pacific Biosciences of California, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Want to learn more about Pacific Biosciences of California, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc.’s Stock Price as of Market Close

As of April 24, 2026, 12:03 PM, CST, Pacific Biosciences of California, Inc.’s stock price was $1.615.

Pacific Biosciences of California, Inc. is up 2.87% from its previous closing price of $1.570.

During the last market session, Pacific Biosciences of California, Inc.’s stock traded between $1.540 and $1.630. Currently, there are approximately 301.91 million shares outstanding for Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Pacific Biosciences of California, Inc. Stock Price History

Pacific Biosciences of California, Inc.’s (PACB) price is currently up 22.35% so far this month.

During the month of April, Pacific Biosciences of California, Inc.’s stock price has reached a high of $1.800 and a low of $1.280.

Over the last year, Pacific Biosciences of California, Inc. has hit prices as high as $2.730 and as low as $0.851. Year to date, Pacific Biosciences of California, Inc.’s stock is down 13.64%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Pacific Biosciences of California, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 23, 2026, there were 0 analysts who downgraded Pacific Biosciences of California, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Pacific Biosciences of California, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Pacific Biosciences of California, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Pacific Biosciences of California, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Pacific Biosciences of California, Inc. (PACB) by visiting AAII Stock Evaluator.

Relative Price Strength of Pacific Biosciences of California, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 23, 2026, Pacific Biosciences of California, Inc. has a weighted four-quarter relative price strength of -4.23%, which translates to a Momentum Score of 41 and is considered to be Average.

Want to learn more about how Pacific Biosciences of California, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Pacific Biosciences of California, Inc. Stock Price: Bottom Line

As of April 24, 2026, Pacific Biosciences of California, Inc.’s stock price is $1.615, which is up 2.87% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Pacific Biosciences of California, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.